We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

5 hedge funds and large institutions have $629K invested in ProShares UltraShort NASDAQ Biotechnology in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more capital invested

Capital invested by funds: $464K → $629K (+$165K)

25% more funds holding

Funds holding: 4 → 5 (+1)

7.65% more ownership

Funds ownership: 13.1% → 20.75% (+7.7%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$201K
2
UBS Group
UBS Group
Switzerland
+$4.13K
3
Simplex Trading
Simplex Trading
Illinois
+$115

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$1.41K
2
TRCT
Tower Research Capital (TRC)
New York
-$955

BIS Hedge Fund Activity: Q2 2025 in Review

5 of the 7,617 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2025, worth a combined $629K — up 36% from $464K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BIS positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $201K. The largest seller was Morgan Stanley, cutting an estimated $1.41K.

  • 5 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2025, up from 4 in Q1 2025.
  • Funds reported $629K of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2025, up 36% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2025 and 0 closed out, a net change of +1 holder.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2025 was Susquehanna International Group, an estimated $201K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2025 was Morgan Stanley, an estimated $1.41K sold.

Based on aggregated 13F filings for Q2 2025.